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Heart failurePerhexiline is a potent anti-anginal drug used for treatment of refractory angina and other forms of heart dis-
ease. It provides an oxygen sparing effect in the myocardium by creating a switch from fatty acid to glucose
metabolism through partial inhibition of carnitine palmitoyltransferase 1 and 2. However, the precise molec-
ular mechanisms underlying the cardioprotective effects elicited by perhexiline are not fully understood. The
present study employed a combined proteomics, metabolomics and computational approach to characterise
changes in murine hearts upon treatment with perhexiline. According to results based on difference in-gel
electrophoresis, the most profound change in the cardiac proteome related to the activation of the pyruvate
dehydrogenase complex. Metabolomic analysis by high-resolution nuclear magnetic resonance spectroscopy
showed lower levels of total creatine and taurine in hearts of perhexiline-treated mice. Creatine and taurine
levels were also signiﬁcantly correlated in a cross-correlation analysis of all metabolites. Computational
modelling suggested that far from inducing a simple shift from fatty acid to glucose oxidation, perhexiline
may cause complex rebalancing of carbon and nucleotide phosphate ﬂuxes, fuelled by increased lactate and
amino acid uptake, to increasemetabolic ﬂexibility and tomaintain cardiac output. This article is part of a Special
Issue entitled "Focus on Cardiac Metabolism".
© 2012 Elsevier Ltd. Open access under CC BY-NC-ND license. 1. Introduction
Perhexiline (2-(2,2-dicyclohexylethyl)piperidine) is an anti-anginal
drug ﬁrst used in France in the 1970's to combat manifestations of
ischaemic heart disease. While withdrawn from the market in the
1980's due to the emergence of unwanted side effects, use of perhexiline
is once again being revived in Australia and New Zealand and to some
extent in Europe [1,2]. Perhexiline's main mode of action is ascribed to
its inhibition of long-chain fatty acid oxidation by inhibition of carnitine
palmitoyltransferase (CPT) 1 and 2 [3]. CPT1 and 2 are responsible for
import of long-chain fatty acids into the mitochondria for β-oxidation.
The predominant source of energy in the heart is derived from fatty
acidmetabolism. In the ischaemic heart there is a switch back to glucose
metabolism reminiscent of foetal programming. However, fatty acidIGE, difference in-gel electro-
rate; GO, Gene ontology; 1H
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NC-ND license. oxidation still predominates and leads to inefﬁcient use of oxygen per
production of ATPmolecule and to uncoupling ofmitochondrial respira-
tion through expression of uncoupling proteins [1,2]. Inhibition of
β-oxidation produces an oxygen sparing effect that has been accom-
panied by improved cardiac function [4]. Perhexiline also exhibits
vasodilatory effects on coronary arteries independently of its CPT in-
hibition activity [5], but this effect is probably clinically not relevant.
Although induction of cardioprotection through metabolic modulation
is a promising therapeutic concept, the precise effects at a molecular
level have yet to be elucidated. The present study investigates changes
in the cardiac proteome and metabolome of perhexiline-treated mice
to assess the drug effects without a priori assumptions and provide in-
sights into potential mechanisms on how this metabolic modulator
may mediate cardioprotection and myocardial salvage.2. Materials and method
Adult male C57BL/6 mice were fed perhexiline prior to proteomic
(n=4 per group) and metabolomic (n=5 per group) analysis of
their hearts as previously described [6]. Detailed methodology is pro-
vided in the online data supplement. Protocols for proteomics are
available on our website at http://www.vascular-proteomics.com.
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3.1. Perhexiline treatment
Perhexiline was fed to C57BL/6 mice for 4 weeks to achieve steady
state concentrations in plasma. The average plasma concentration of
perhexiline was 0.51±0.28 μg/ml, which was within the therapeutic
range (0.15–0.60 μg/ml). The average concentration of its metabolite,
hydroxyperhexiline, was 0.80±0.24 μg/ml.
3.2. Proteomics
Proteomic analysis of perhexiline-treated hearts compared to nor-
mal hearts was performed by difference in-gel electrophoresis (DIGE)
using a broad-range pH gradient (pH 3–10 non-linear, n=4 per
group) (Fig. 1A). Differentially expressed spots were excised, subjected
to in-gel tryptic digestion, and identiﬁed using liquid chromatography
tandem mass spectrometry (LC-MS/MS) (Supplemental Table 1).
The identiﬁed proteins showed enrichment (FDRb5%, Supplemental
Table 2) for the GO Biological Process term ‘gas transport’ and GO
terms related to the oxygen transport (‘oxygen binding’, ‘oxygen
transport’, and ‘oxygen transporter activity’), mainly due to an increase
in haemoglobin,whichmay be a consequence of the vasodilatory effects
of perhexiline. The larger proportion of enriched terms consisted of
those relating to metabolic and catabolic processes, including the GO
term ‘cellular carbohydrate catabolic process’ (P=2.48×10−04).
3.3. Enzymatic changes
Themost pronounced changes involvedmetabolic enzymes, especial-
ly those involved in glucose and lipid metabolism. A decrease in
long-chain speciﬁc acyl-CoA dehydrogenase, an acyl-CoA acceptor Mr 
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Fig. 1. Effect of perhexiline on cardiac protein expression. A) Cardiac protein extracts from c
DIGE (n=4 per group). Differentially expressed spots were numbered and identiﬁed by LC-M
different isoforms of the α subunit of the pyruvate dehydrogenase E1. The observed decrea
basic isoforms (red colour) is consistent with dephosphorylation of the regulatory subun
dye-swap (lower panel). C) Phosphate-afﬁnity gel electrophoresis formobility shift detection of
of the α subunit of the pyruvate dehydrogenase E1 (upper panel, phosphorylated bands markenzyme involved in processing long chain fatty acids during
β-oxidation, was accompanied by a compensatory increase in fatty acid
binding protein (responsible for binding long chain fatty acids) and dif-
ferential expression of themedium-chain speciﬁc acyl-CoA dehydroge-
nase. This enzyme is an acyl-CoA acceptor involved in β-oxidation but
speciﬁc for shorter acyl chain lengths between 4–16 carbons. Differen-
tial expression was observed for adenylate kinase isoenzyme 4, which
produces ATP and AMP from ADP, as well as 2-oxoisovalerate dehydro-
genase subunitα. The latter is part of a complex involved in amino acid
metabolism that catalyses the conversion of α-ketoacids to acyl-CoA. In
terms of glucose metabolism, the most profound changes, involved the
regulatory subunit of pyruvate dehydrogenase (PDH-E1α, Fig. 1B).
3.4. PDH complex
Four different pyruvate dehydrogenase kinases phosphorylate
three sites on the E1α regulatory subunit to inactivate the PDH complex.
The different isoformswere visible as a charge train of spots with similar
molecular weight but different isoelectric points (Fig. 1B). The observed
shift from acidic to basic isoforms in response to perhexiline is consistent
with decreased phosphorylation and was independently conﬁrmed by
immunoblotting (Fig. 1C).
3.5. Metabolomics
Next, cardiac metabolites were extracted and subjected to high-
resolution 1H NMR spectroscopy (Fig. 2A, n=5 per group). The meta-
bolic proﬁles clearly discriminated control and perhexiline-treated
hearts (Fig. 2B). As expected, perhexiline treatment resulted in a de-
crease in acetate, the end product of lipid metabolism, although it fell
short of statistical signiﬁcance (p=0.086, Supplemental Table 3). In a
cross-correlation analysis, ﬁve pairs of metabolites were signiﬁcantly62 
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ontrol (green colour) and perhexiline-treated (red colour) mice were quantiﬁed using
S/MS (Supplemental Table 1). B) Enlargement of the boxed area in panel A to highlight
se of the more acidic forms (green colour) with a corresponding increase of the more
it (upper panel). Results were reproduced with different biological replicates using a
phosphorylatedproteins. Separation of phosphorylated and non-phosphorylated isoforms
ed with an arrow) without differences in protein abundance (lower panel).
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correlated with valine, β-hydroxybutyrate and alanine. Alanine and
beta-hydroxybutyratewere also signiﬁcantly correlated aswere taurine
and creatine (Supplemental Table 4). Both showed a signiﬁcant reduction
in perhexiline-treated hearts (Supplemental Table 3). The hierarchical
clustering in Fig. 2C illustrates that while many of the metabolites are
closely correlated, indicated by the short branches of the tree, taurine
has the largest separation from the restwith lactate and creatine together
showing the next largest separation (pb0.01). The clustering also re-
vealed that glutamate, alanine and succinate cluster together, suggesting
that thesemetabolitesmayplay a role in the samemetabolic pathway [7].
Fig. 2D highlights the loss of mutual information for features like taurine,
a degradation product of cysteine, and fumarate, a TCA cycle metabolite
that has been proposed to be cardioprotective [8], in perhexiline-treated
hearts (Fig. 2D).
3.6. Computer simulations
Finally, we simulated the effects of perhexiline on myocardial
metabolism using a well-validated proteome-scale network model
(Supplemental Fig. 1, Supplemental Table 5): In our simulations, medi-
an lactate uptake increased more than threefold contributing to a ﬁve-
fold increase in median PDH ﬂux (Supplemental Fig. 2). This is in line
with a previous report [9] that perhexiline alters metabolic substrate
use from free fatty acids to lactate through altered PDH complexA
C
Fig. 2. Effect of perhexiline on cardiac metabolite expression. A) Cardiac metabolite express
NMR spectroscopy. Sodium 3-trimethylsilyl-2,2,3,3-tetradeuteropropionate (TSP) was adde
provided in Supplemental Table 3. B) Principal Component Analysis on the set of metabolit
and perhexiline-treated hearts (red). C) Clustering of cardiac metabolites in the dendrogram
likelihood of relatedness algorithm. The lower and upper triangles of each heatmap correspo
Thus, comparison of the lower and upper triangles visualizes model-based differences in refunction. Similarly, our proteomic data showed unchanged or even re-
duced glycolytic enzymes but an increase in lactate dehydrogenase
and PDH activation (Supplemental Table 1). There was also a 60% in-
crease in pyruvate kinase ﬂux (and thus increase in substrate-level
phosphorylation [7]), driven by increased phosphoenolpyruvate syn-
thesis by phosphoenolpyruvate carboxykinase (up 80%). However,
these increases were insufﬁcient to maintain acetyl-CoA delivery and
ﬂux through the TCA cycle to alpha-ketoglutarate (AKG) was below
control rates. Increased amino acid uptake (e.g. median glutamate up-
take increased threefold) supplemented the TCA cycle at several points,
such that ﬂux from AKG to citrate was increased well above control
levels (Supplemental Fig. 2). Thus, perhexiline may cause complex
rebalancing of carbon and nucleotide phosphate ﬂuxes, fuelled by in-
creased lactate and amino acid uptake, to increase metabolic ﬂexibil-
ity and to restore energy homeostasis to maintain cardiac output
[10,11].
3.7. Limitations
Further studies are required to assess the effects of perhexiline on
PDH activity, in order to determine if PDH is a direct or indirect drug
target. It has been shown that perhexiline accumulates within cardiac
mitochondria due to its ability to form tight but reversible interactions
with mitochondrial phospholipids. Within the mitochondrial matrix
perhexiline molecules may donate their protons thus altering theB
D
ion in control and perhexiline-treated mice (n=5 per group) was quantiﬁed using 1H
d to the samples for chemical shift calibration and quantiﬁcation. Quantitative data are
es quantiﬁed by 1H NMR spectroscopy allowed a clear discrimination of control (blue)
. D) Mutual information heatmaps between all metabolites, calculated using the context
nd to metabolite similarities in the control and perhexiline-treated hearts, respectively.
latedness of metabolite proﬁles in response to perhexiline treatment.
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activate the PDH complex [12,13]. Similar changes may occur with
other cardioprotective agents, such as etomoxir, trimetazidine and
ranolazine, and constitute part of the Randle cycle [14]. Also, an analysis
of themitochondrial subproteomemayhave revealed additionalmolec-
ular targets, i.e. CPTs that were not identiﬁed in our analysis.
4. Conclusion
This study is the ﬁrst proteomic and metabolomic evaluation of
cardiac effects induced by a metabolic modulator. Our data suggest
that besides suppressing fatty acid metabolism, perhexiline is likely to
have more wide-ranging and complex systemic effects than previously
thought (due to stoichiometric constraints) and shows that computa-
tional modelling combined with proteomics and metabolomics [15]
provides a unique view of systemic metabolism and drug action.
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